Company profile
UPSTREAM BIO, INC.
NASDAQ:UPBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VEREKITUG | phase2 | — | 6 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06966479 | phase2 | active_not_recruiting | 2025-05-21 | 2027-09-01 | Upstream Bio Inc. | A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) |
| NCT06981078 | phase2 | active_not_recruiting | 2025-07-02 | 2027-10-01 | Upstream Bio Inc. | A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD |
| NCT06196879 | phase2 | completed | 2024-02-27 | 2025-12-16 | Upstream Bio Inc. | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) |
| NCT06164704 | phase2 | completed | 2023-12-18 | 2025-07-07 | Upstream Bio Inc. | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps |
| NCT05448651 | phase1 | completed | 2022-07-08 | 2023-08-15 | Upstream Bio Inc. | Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics |
FDA applications (0)
No records yet.